Compare Kohl's Corporation (KSS) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kohl's Corporation vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Kohl's Corporation trades at $21.11 (market cap $2.39B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Kohl's Corporation is far larger — about 2.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Kohl's Corporation pays a 2.37% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kohl's Corporation for 48 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| KSS | MRVI | |
|---|---|---|
Market Cap | $2.39B | $972.90M |
Volume | 4,591,325 | 4,325,710 |
Sector | Consumer Cyclical | Health |
52-Week High | $24.71 | $9.00 |
52-Week Low | $11.72 | $2.83 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | $7.99B | $1.08B |
Dividend Yield | 2.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kohl's (KSS) trades at $21.15, down slightly by 0.09% on the day, with the stock showing bullish technical signals from moving averages. The company has beaten earnings expectations for three consecutive quarters, including a significant Q2 2026 beat of $1.28 EPS versus $0.58 expected. Despite declining revenues, Kohl's maintains attractive valuation metrics with a P/E of 9.06 and P/S of 0.16, while recent management changes and operational improvements provide potential catalysts.
The investment case centers on deep value metrics and operational turnaround potential, though persistent revenue declines and competitive pressures remain key risks. Analyst sentiment is mixed with 30% buy ratings but a consensus price target of $15.50 below current levels, suggesting cautious optimism about the company's ability to stabilize sales and improve profitability in a challenging retail environment.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
